Tag: Mismatch repair-deficient therapy

Home / Mismatch repair-deficient therapy

Categories

Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer

  June 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with carboplatin and paclitaxel, followed by singl...
mismatch-repair-deficient-therapy

Scan the code